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PURPOSE. To determine the sensitivity of the combination of optical coherence tomography
angiography (OCTA) and structural optical coherence tomography (OCT) for detecting type 1
neovascularization (NV) and to determine significant factors that preclude visualization of
type 1 NV using OCTA.
METHODS. Multicenter, retrospective cohort study of 115 eyes from 100 patients with type 1
NV. A retrospective review of fluorescein (FA), OCT, and OCTA imaging was performed on a
consecutive series of eyes with type 1 NV from five institutions. Unmasked graders utilized FA
and structural OCT data to determine the diagnosis of type 1 NV. Masked graders evaluated FA
data alone, en face OCTA data alone and combined en face OCTA and structural OCT data to
determine the presence of type 1 NV. Sensitivity analyses were performed using combined FA
and OCT data as the reference standard.
RESULTS. A total of 105 eyes were diagnosed with type 1 NV using the reference. Of these, 90
(85.7%) could be detected using en face OCTA and structural OCT. The sensitivities of FA data
alone and en face OCTA data alone for visualizing type 1 NV were the same (66.7%).
Significant factors that precluded visualization of NV using en face OCTA included the height
of pigment epithelial detachment, low signal strength, and treatment-na¨ıve disease (P < 0.05,
respectively).
CONCLUSIONS. En face OCTA and structural OCT showed better detection of type 1 NV than
either FA alone or en face OCTA alone. Combining en face OCTA and structural OCT
information may therefore be a useful way to noninvasively diagnose and monitor the
treatment of type 1 NV.
Keywords: optical coherence tomography angiography, fluorescein angiography,
neovascularization, image analysis, age-related macular degeneration
Choroidal neovascularization (CNV) is a vision-threaten-ing complication of chorioretinal diseases.1 Type 1 NV
is the most common subtype of neovascular age-related
macular degeneration (AMD) and is characterized by
pathologic angiogenesis in the sub–retinal pigment epithe-
lium (RPE) compartment.2–4 Other conditions that are
commonly associated with type 1 NV include the pachych-
oroid-related spectrum5–7 of diseases including central
serous chorioretinopathy (CSC),8,9 pachychoroid neovascul-
opathy (PNV),10 and polypoidal choroidal vasculopathy
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(PCV).6,10 The prevalence of conditions associated with
type 1 NV is projected to substantially increase over the
next two decades,1 and there remains an important need to
improve the diagnostic and therapeutic outcomes related to
these disorders.
The current standard for diagnosing NV relies upon the
integration of fluorescein angiography (FA) and structural
optical coherence tomography (OCT).11,12 Optical coher-
ence tomography is a rapid, safe, and noncontact imaging
modality that provides high-resolution anatomical informa-
tion about retinal and choroidal structures.13 Fluorescein
angiography, on the other hand, is an invasive, prolonged
investigation that permits wide-field examination of the
retina and provides information about vascular leakage,
staining, and pooling.14 There are disadvantages of FA
including the need for intravenous dye injection and the
risk of nausea and vomiting, allergy and, rarely, anaphylax-
is.15–17 For these reasons, frequent FA examinations are not
commonly used to monitor the clinical course of neovascu-
lar diseases.
Optical coherence tomography angiography (OCTA) is a
new technique that detects vascular structures using motion
or flow characteristics. Optical coherence tomography
angiography provides fast, noninvasive, depth-resolved vas-
cular information and has been proposed by some investiga-
tors as a suitable replacement for FA. However, there are
several patient and disease-related factors that are known to
preclude reliable visualization of NV using OCTA18 and the
utility of OCTA for managing NV remains unclear. The
purpose of this report is to evaluate the sensitivity of en face
OCTA alone and combined en face OCTA and structural OCT
data for diagnosing type 1 NV. The sensitivity of these
techniques is determined by comparison to the reference
standard which includes FA combined with structural OCT
data. The sensitivity of FA alone for detecting type 1 NV is also
evaluated in this report. Results from an international,
multicenter study are provided.
METHODS
Study Design
The comparison of OCTA to FA for the imaging of type 1
neovascularization (COFT-1) trial was an international, multi-
center cohort study. This retrospective study design was
approved by the institutional review boards at each participat-
ing center. It complied with the health insurance portability
and accountability act of 1996 and followed the tenets of the
Declaration of Helsinki.
Data Collection
We retrospectively reviewed the charts and imaging data of a
consecutive series of eyes (both treatment na¨ıve and treated)
with type 1 NV secondary to AMD, CSC, PNV, and PCV.
Polypoidal choroidal vasculopathy was diagnosed using a
combination of imaging techniques including OCT, FA, and
indocyanine green angiography. Pachychoroid neovasculop-
athy was defined as a form of type 1 NV occurring over areas of
pachyvessels that exceeded the choroidal diameter seen in
normal eyes.5 The diagnosis of each form of type 1 NV was
performed at the individual institutions. All imaging studies
were performed between August 1, 2014, and August 1, 2015,
at one of five tertiary referral institutions, which involved four
sites in the United States and one site in France. Only eyes that
underwent OCTA using the spectral domain (SD)-OCT device
(Optovue RTVue XR Avanti; Optovue, Inc., Fremont, CA, USA)
and concomitant FA and OCT imaging within 7 days were
included. Eyes that received treatment with anti–vascular
endothelial growth factor (VEGF) therapy or photodynamic
therapy (PDT) between imaging studies were excluded.
Fluorescein angiography was performed with a commercial
OCT device (Heidelberg Spectralis HRA þ OCT; Heidelberg
Engineering, Heidelberg, Germany). Spectral-domain OCT
imaging (Heidelberg Spectralis HRA þ OCT; Heidelberg
Engineering or Cirrus high-definition OCT; Carl Zeiss Meditec,
Dublin, CA, USA) including enhanced depth imaging OCT was
performed on all eyes.
Patient demographic characteristics at the time of FA and
OCTA imaging including age, sex, and previous treatments
were recorded. The Snellen best-corrected visual acuity (BCVA)
was also recorded and converted to logarithm of the minimum
angle of resolution (logMAR) for statistical analysis.
Optical Coherence Tomography Angiography
The optical coherence tomography angiography system that
was used in this study was the Optovue RTvue XR Avanti
(Optovue, Inc.). This system utilizes an A-scan rate of 70,000
scans per second, a light source centered on 840 nm and a
bandwidth of 45 nm to obtain split-spectrum amplitude-
decorrelation angiography images. Each OCTA volume con-
tains 3043304 A-scans with two consecutive B-scans captured
at each fixed position before proceeding to the next sampling
location.19 Angiography information displayed is the average of
the decorrelation values when viewed perpendicularly through
the thickness being evaluated.
To ensure consistent image selection, raw data (en face
OCTA and structural OCT) obtained on the AngioVue from all
five centers were sent to one institution. One of the unmasked
investigators chose the best quality images of en face OCTA (3
3 3 mm) and structural OCT for analysis (Fig. 1). Automated
segmentation was used to visualize neovascular tissue in the
plane above Bruch’s membrane. However, when automated
techniques failed, the areas of segmentation were manually
adjusted until the tissue of interest was visualized.
Unmasked Evaluation of Neovascularization
Figure 1 is a flowchart that illustrates the study design.
Selection of suitable cases was initially undertaken at each of
the five centers participating in this study. Fluorescein
angiography and OCT information from the entire data set
was then reviewed by two unmasked graders (MI, KD) to
confirm type 1 NV. Fluorescein angiography information that
was used to diagnose NV consisted of single frames from the
early and late stages of the angiogram. Type 1 NV on FA was
defined as ‘‘present’’ if there were any characteristic signs of
CNV on FA including stippled hyperfluorescence and/or late
hyperfluorescent leakage. Eyes determined to have type 2
(subretinal), type 3 (retinal angiomatous proliferation, intraret-
inal) and mixed NV were excluded from further analysis.
Additional features that were recorded from structural OCT
scans included presence/absence of exudative change, maxi-
mum width of pigment epithelial detachment (PED), and
maximum height of PED. Length of PED was measured using
the caliper function or analysis tools in the Fiji distribution (Fiji
is just ImageJ [http://imagej.nih.gov/ij/; provided in the public
domain by the National Institutes of Health, Bethesda, MD,
USA], http://fiji.sc).20
En face OCTA images from eyes that were deemed to have
type 1 NV on FA and OCT were then evaluated by unmasked
graders. The ability to visualize NV on en face OCTA was
graded in a binary fashion: present or absent. When type 1 NV
was seen on en face OCTA images it was categorized into one
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of 2 types: tangled pattern21 or filamentous pattern.22
Qualitative comparisons were made between FA and en face
OCTA with respect to size and morphologic appearances of
neovascular lesions. The appearance of NV as imaged by en
face OCTA at sites of FA leakage or staining was also evaluated.
Masked Evaluation of Sensitivity of FA and OCTA
Two retina specialists who were blinded to the purpose and
results of the study evaluated the FA alone, en face OCTA
alone, and combined en face OCTA with structural OCT. The
structural OCT B-scans from the same raw data acquired by
the SD-OCTA were utilized to provide for uniform grading.
Grading for NV was performed in a binary manner (1 ¼
present, 0¼ absent). Fluorescein angiography, en face OCTA,
and combined en face OCTA with structural OCT were
evaluated separately and additional patient information was
not provided. When the evaluation was inconsistent, a third
masked reader made the final arbitration. Sensitivity of FA
alone, en face OCTA alone, and combined en face OCTA with
structural OCT for diagnosing type 1 NV was determined by
comparing it against the reference, the analysis of unmasked
graders using combined structural OCT and FA information.
Statistical Analysis
Kruskal-Wallis 1-way ANOVA on ranks was used to compare
demographic characteristics between AMD, CSC, PNV, and
PCV groups. Scheffe multiple comparison test was used to
compare the data within each group.
Logistic regression analysis was used to determine the
influence of different variables including age, sex, cause of
type 1 NV (AMD or pachychoroid-related diseases), treatment
(treatment-na¨ıve or treated), BCVA, presence/absence of
exudative change, width and height of PED, signal strength
of OCTA images, and the ability to visualize type 1 NV on FA or
on en face OCTA.
Agreement between masked observers was assessed using
the kappa statistic which was defined as follows: greater than
0.81 represents ‘‘excellent’’ agreement; 0.61–0.80 represents
‘‘good’’ agreement; 0.41–0.60 represents ‘‘moderate’’ agree-
ment and less than 0.40 represents ‘‘poor’’ agreement.23 The
interobserver reproducibility of en face OCTA and FA was
compared using Fisher’s exact test. Statistical analysis was
performed using statistical software (SPSS software Version 21;
SPSS, Inc., Chicago, IL, USA). A value of P < 0.05 was
considered significant.
FIGURE 1. A flow chart to illustrate study design.
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RESULTS
Patient Characteristics
A total of 115 eyes of 100 patients, which were sent as type 1
NV from 5 institutions, were evaluated by unmasked graders.
Ten eyes were determined to have type 2 or type 3 NV and were
excluded from the study resulting in a total of 105 eyes of 92
patients. Demographic and clinical characteristics of patients
with type 1 NV are shown in Table 1. Mean patient age was 73.1
6 11.7 years (median, 73 years; range, 44–95 years). Forty-nine
(46.7%) of the patients had received previous treatment with
intravitreal anti-VEGF therapy, PDT, or laser photocoagulation.
Mean logMAR BCVA was 0.44 (20/55 Snellen equivalent). Mean
signal strength of OCTA images was 59.6 6 9.1.
Type 1 NV was due to AMD in 59 eyes (56.2%), CSC in 22
eyes (21.0%), PNV in 2 eyes (1.9%) and PCV in 22 eyes (21.0%).
The demographic and lesion characteristics of each of the
subgroups with type 1 NV are summarized in Table 2. Patient
characteristics such as age, sex, and BCVA were significantly
different between the four groups. Mean BCVA was better in
the PCV group than the neovascular AMD group (P ¼ 0.021),
but there were no significant differences between other groups
(all P > 0.05). Age was significantly higher in the neovascular
AMD group than in the CSC and PCV groups (P < 0.001 and P
¼ 0.001, respectively).
Unmasked Evaluation of Neovascularization
A total of 71 of 105 eyes (67.6%) demonstrated a tangled
pattern of NV with en face OCTA and five eyes (4.8%)
showed a filamentous pattern of NV on en face OCTA (Figs. 2,
3). The boundaries of the areas of NV appeared clearly
defined on en face OCTA images. Type 1 NV was not
identified with en face OCTA in 29 eyes (27.6%) that were
deemed to have type 1 NV by unmasked graders using the
reference (Fig. 4). A tall PED (>2000 lm) as localized at the
site of NV in 17 of these 29 eyes and a significant loss of
signal intensity was observed beyond the outer margins of
the RPE in these eyes (Fig. 4).
Of the 76 eyes that demonstrated type 1 NV with en face
OCTA, 61 (80.3%), were localized within sites of fluorescein
leakage/staining (Figs. 2, 3). In the remaining 15 eyes (19.7%),
en face OCTA identified type 1 NV at sites where fluorescein
leakage/staining was not observed (Fig. 5). There were no
discernible differences in the structure and flow signatures of
NV with en face OCTA between areas of fluorescein leakage
and staining. The area of NV frequently appeared larger on FA
compared to en face OCTA due to the occurrence of RPE
window defects and fluorescein leakage/staining. In 39 cases
(51.3%), a large or small dark ring was identified around the NV
with OCTA (Fig. 6).
Masked Grading Outcomes and Sensitivity
Analyses
A diagnosis of type 1 NV was confirmed using FA alone in 70
eyes, en face OCTA alone in 70 eyes and combined en face
OCTA with structural OCT in 90 eyes by the masked readers.
The sensitivity for the detection of type 1 NV using FA alone,
en face OCTA alone and combined en face OCTA with
structural OCT was therefore 66.7% (70/105), 66.7% (70/
105), and 85.7%, (90/105) respectively, compared with the
reference. Interobserver agreement was moderate with a
kappa value of 0.454 (standard error 60.078, P < 0.001) for
FA alone, good with 0.686 (standard error 60.072, P <
0.001) for en face OCTA alone and 0.660 (standard error
60.105, P < 0.001) for combined en face OCTA and
structural OCT data. The interobserver agreement for en
face OCTA (P ¼ 0.026) and combined en face OCTA with
structural OCT (P < 0.001) was significantly greater than FA
alone, respectively.
Factors Influencing Detection of
Neovascularizaton
Logistic regression analysis of FA data acquired from masked
readers showed that detection of type 1 NV correlated
TABLE 1. Demographic and Clinical Characteristics of Eyes With Type
1 NV
Total eyes 105
Number of patients, n (%) 92
Male 54 (58.7)
Female 38 (41.3)
Age, mean 6 SD, year (range) 73.1 6 11.7 (44–95)
Side (right/left) 52/53
Mean logMAR BCVA (Snellen equivalent) 0.44 6 0.40 (20/55)
Origin of type 1 NV, n (%)
Neovascular AMD (%) 59 (56.2)
CSC 22 (21.0)
PNV 2 (1.9)
PCV 22 (21.0)
Previous treatment, n (%)
Anti-VEGF 43 (41.0)
Anti-VEGF þ PDT 1 (1.0)
Anti-VEGF þ PDT þ laser
photocoagulation 2 (1.9)
Laser photocoagulation 3 (2.8)
None 56 (53.3)
Mean signal strength of OCTA images 59.6 6 9.1
Appearance of NV on OCTA, n (%)
Tangled vessel pattern 71 (67.6)
Filamentous pattern 5 (4.8)
Not detected 29 (27.6)
TABLE 2. Comparison of Characteristics for Each Origin of Type 1 NV
Neovascular AMD, n ¼ 59 CSC, n ¼ 22 PNV, n ¼ 2 PCV, n ¼ 22 P Value*
Patient 48 21 2 22
Number of males/females 21/27 15/6 2/0 17/5 0.016
Age, years, mean 6 SD 79.7 6 8.7 62.2 6 11.7 73.0 6 2.8 68.8 6 7.2 <0.001
Baseline logMAR visual acuity, mean 6 SD 0.51 6 0.39 0.35 6 0.33 0.15 6 0.21 0.35 6 0.49 0.005
Previous treatment, þ/ 23/36 9/13 1/1 16/6 0.054
Identified/unidentified of NV on OCTA 38/21 17/5 1/1 19/3 0.203
Mean signal strength of the OCTA image 57.9 6 8.6 62.1 6 11.4 62.0 6 11.3 61.5 6 7.1 0.127
To compare the characteristics for each, origin of type 1 NV was investigated using the Kruskal-Wallis test.
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significantly to the cause of type 1 NV (P ¼ 0.045; Table 3).
Type 1 NV was visualized more frequently in eyes with
pachychoroid spectrum on FA. Analysis of the en face OCTA
data showed that detection of type 1 NV significantly
correlated to OCTA signal strength (P ¼ 0.034); treatment
history (P¼0.006); and PED height (P¼0.018). Type 1 NV was
more frequently visualized in eyes with a higher signal
strength, shallower PED, and a history of previous treatment.
However, detection of type 1 NV on OCTA was not significantly
correlated to the cause of the type 1 NV (P ¼ 0.789).
DISCUSSION
The prevalence of AMD is projected to rise in the developed
world in the next two decades, and, in some countries, the
increase is predicted to be as high as 75% by 2040.1 Refining
our ability to visualize NV in AMD may be one way to reduce
the clinical burden and visual morbidity associated with this
disease. Integration of FA and OCT information is currently
considered the standard for diagnosing NV.11,12 However, the
invasive nature and potential adverse effects of FA preclude its
frequent use in the clinical setting. Other drawbacks of FA
include its inability to estimate accurately the expanse of NV
and differentiate leakage from staining or RPE window defects
in some settings. A recent study suggested that the sensitivity
and specificity of OCTA, with the use of corresponding
structural OCT, for detecting type 1 and mixed (type 1 and
2) NV in CSC could be as high as 100%.24 The purpose of this
multicenter study was to define the sensitivity of OCTA for
diagnosing type 1 NV in neovascular AMD, CSC, PNV, and PCV
and to ascertain if it is an adequate replacement for the current
standard (FA and OCT).
In this study, we found that the sensitivity for detecting type
1 NV using OCTA data combined with structural OCT
information was 85.7%. In comparison, the sensitivity of en
face OCTA alone and FA alone for detecting type 1 NV was the
same (66.7%). The higher sensitivity for detection achieved by
combining OCTA and structural OCT data suggests that it may
FIGURE 2. Tangled morphology of type 1 neovascularization as imaged with FA and en face OCTA in an eye with age-related macular degeneration.
(A) Early-phase FA of the right eye shows several irregular areas of hyperfluorescence. (B) Late-phase FA shows areas of poorly defined leakage and
staining. (C) Magnified view of early-phase FA shows poorly defined irregular borders of the lesion (arrowheads). (D) A tangled pattern within the
neovascular lesion is seen on the corresponding OCTA. The localization of neovascularization on en face OCTA correlates with the hyperfluorescent
area on FA (yellow arrowheads). (E) The structural OCT provides details about the plane of segmentation of the en face OCTA. A fibrovascular
pigment epithelial detachment with subretinal hyperreflective exudation is seen.
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be a useful technique for the noninvasive, clinical diagnosis of
type 1 NV. It may also potentially translate to a reduced need
for FA in these settings.
Previous reports have suggested that FA and stereo color
photographs are the best method for detecting new onset
choroidal NV.25 In the current study, the overall sensitivity of
conventional FA alone for detecting NV was lower than
expected, and this may be because stereoscopic FA and color
photographs were not used. Over the past several years,
stereoscopic photography has been performed less commonly
due to the availability of digital imaging and the time-
consuming nature of color and FA stereoscopic photography
which limit their use in daily clinical practice.
In this study, the interobserver agreement for OCTA was
greater than for FA suggesting a greater degree of reproduc-
ibility in the interpretation of OCTA images. This finding
suggests that there may be more subjectivity with FA
interpretation compared with OCTA.
An important finding in this study was that NV was not
visualized using en face OCTA alone in 27.6% of eyes that
were deemed to have type 1 NV by the reference. This finding
is consistent with a previous study investigating type 1 NV in
neovascular AMD.18 Logistic regression analysis identified
three significant variables that influenced identification of
type 1 NV, and these included the height of PEDs, the signal
strength of the scan and a history of prior treatment for NV.
The most frequent reason that NV was not detected using en
face OCTA was the presence of a relatively tall PED at the site
of NV. Pigment epithelium detachments have the capacity to
attenuate the OCT signal and can preclude visualization of
vascular structures beyond the RPE layer. Cataract, media
opacities, poor fixation, and projection artifacts of retinal
vessels on OCTA can compound this problem further and
diminish the quality of OCTA images.26 Interestingly, the
detection rate of type 1 NV with en face OCTA was
significantly greater in eyes with a history of treatment. This
FIGURE 3. Filamentous morphology of type 1 neovascularization (NV) as imaged with FA and en face OCTA in an eye with central serous
chorioretinopathy. (A) Early-phase FA of the left eye shows an area of faint hyperfluorescence inferior and nasal to the macula. (B) Magnified view of
the early-phase FA. (C) Late-phase FA shows leakage (arrowheads). An inferior area of hyperfluorescence due to a window defect is also seen
(arrows). (D) Corresponding en face OCTA demonstrates NV (yellow arrowheads) of filamentous morphology within the area of FA leakage. (E)
Enhanced-depth imaging OCT shows a shallow irregular PED with overlying subretinal fluid at the site of NV and demonstrates underlying
pachyvessels beneath the PED (arrowheads).
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finding is also consistent with a previous report which
showed that maturation and abnormalization of neovascular
vessels occurs following continuous anti-VEGF therapy.18,21
Chronic, multilayered fibrovascular PEDs likely contain more
mature fibrovascular type 1 complexes and are more readily
visualized by en face OCTA compared to treatment-na¨ıve
eyes.18,27
Our study showed that the localization of NV with en face
OCTA correlated with sites of leakage or staining on FA in most
cases. Furthermore, in some eyes, type 1 NV was detected with
en face OCTA in areas where it was not detected with FA.
Although we cannot rule out the possibility of a false positive
interpretation, this finding suggests that some type 1 lesions
visible on en face OCTA could represent quiescent vessels that
may not leak fluorescein dye. Currently, it remains unclear if
quiescent lesions seen on OCTA require anti-VEGF therapy and
longitudinal studies will be required to define the natural
course of these lesions. With regard to those lesions seen on
OCTA that demonstrated leakage on FA, we were unable to
identify any specific OCTA imaging biomarkers that seemed to
correlate with the degree of leakage present in active NV seen
on conventional FA. Therefore, OCTA still remains limited in its
ability to identify leakage and activity of type 1 NV compared
with conventional FA.
In this study, 51.3% of cases demonstrated a small or large
dark ring around the type 1 NV on OCTA. Jia and colleagues28
first described the association of a ‘‘halo’’ finding in some cases
of CNV imaged with OCTA. They described that the halo
seemed to be due to mechanical compression of the
underlying choriocapillaris from the exudative changes leading
FIGURE 4. An example of en face OCTA failing to show neovascularization in an eye with AMD despite visualization by FA. (A) Early-phase FA shows
an area of stippled hyperfluorescence with irregular borders. (B) A magnified view of the early-phase FA. Well-defined borders of the vascularized
PED are seen (arrowheads). (C) Late-phase FA shows hyperfluorescent staining of a vascularized PED. (D) The corresponding en face OCTA
demonstrates low signal and an absence of flow signature at the site of the PED (yellow arrowheads). (E) The structural OCT illustrates a tall PED
and identifies the plane of en face OCTA segmentation.
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to alterations in normal blood flow in the choriocapillaris and
darkening on OCTA imaging.28 Previous histologic analysis by
McLeod and colleagues29 supported this hypothesis and
demonstrated that choriocapillaris dropout was evident in
the absence of RPE adjacent to active NV. In our study, we
noted the dark halo in some eyes both with and without
intraretinal and/or subretinal fluid visible on structural OCT.
This observation suggests that there may be additional
explanations for the halo including changes in imaging
artifacts, including projection artifacts, occurring at the edges
of elevated vascularized PEDs. Another possibility is lower flow
rates occurring at the margins of certain neovascular lesions. It
is possible that attenuation of flow at the edges of some lesions
may be below the detection level currently utilized in some
OCTA algorithms.
Limitations of this study include its retrospective nature and
a lack of overall uniformity of case selection due to the
participation of multiple institutions. The manual detection of
type 1 NV on en face OCTA could be reader dependent. To
minimize this confounding factor, we designed the study such
FIGURE 5. Comparison of FA and en face OCTA. (A) Early-phase FA image shows multiple areas of irregular hyperfluorescence. (B) Magnified view
of the early-phase FA. (C) Late-phase FA shows multiple areas of hyperfluorescent staining. Note the absence of hyperfluorescence in the central
macula (asterisk). (D) Corresponding en face OCTA shows NV with tangled morphology. Note that there are areas of NV clearly visualized on en
face OCTA that are not detected on FA (yellow asterisk). The margins of the lesion also appear better defined on en face OCTA (white arrow heads).
(E) The structural OCT provides details about the plane of segmentation of the en face OCTA. A shallow irregular PED is seen.
TABLE 3. Logistic Regression Analysis on FA and OCTA in Detecting
NV
Variables
FA OCTA
P
Value
Odds
Ratio
P
Value
Odds
Ratio
Age 0.227 1.032 0.750 1.010
Sex 0.087 2.340 0.723 1.216
Cause of type 1 NV (AMD
or pachychoroid spectrum) 0.045 3.477 0.789 1.190
Treatment (treatment-na¨ıve
or treated) 0.423 1.455 0.006 4.851
logMAR visual acuity 0.152 2.638 0.819 0.863
Exudative changes on OCT 0.539 1.366 0.245 1.915
Width of PED 0.412 1.000 0.886 1.000
Height of PED 0.487 1.001 0.018 0.993
Signal strength of the OCTA image – – 0.034 1.070
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that the unmasked grader prepared the best images of type 1
NV as seen on OCTA for evaluation by masked graders.
Furthermore, because we had already made the determination
that all of the eyes had type 1 NV based upon the findings of FA
and OCT, it was not possible to evaluate the specificity of
OCTA in this study. Finally, it will be important to investigate
the sensitivity of swept-source OCTA for detecting type 1 NV
and to determine if it is different to SD-OCTA.
A strength of the study is the comparison of contempo-
raneous information acquired using FA, OCT, and OCTA from
a relatively large cohort of subjects. The findings of this study
suggest that en face OCTA and structural OCT does not
replace the current standard (FA and OCT) in the diagnosis of
type 1 NV. Rather, our findings demonstrate the effectiveness
of OCTA as an adjunctive imaging modality that complements
the information derived from FA. It is possible that
noninvasive multimodal imaging, including the combination
of en face OCTA and structural OCT will serve an important
future role in the diagnosis and management of neovascular
diseases involving the choroid. However, further longitudinal
information will be required to clarify the role of OCTA in
clinical practice and to determine if it is a suitable
replacement for FA.
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